Milvexian and other drugs targeting Factor XI: a new era of anticoagulation?
For almost 90 years, the discovery and development of anticoagulant drugs have focused on maximizing their antithrombotic efficacy while minimizing the risk of bleeding, in addition to providing manageable compounds with predictable and/or monitorable effects [...].
Main Authors: | Marco P. Donadini, Walter Ageno |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2022-04-01
|
Series: | Bleeding, Thrombosis and Vascular Biology |
Subjects: | |
Online Access: | https://btvb.org/btvb/article/view/22 |
Similar Items
-
Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy
by: João Presume, et al.
Published: (2024-02-01) -
Factor XI, a potential target for anticoagulation therapy for venous thromboembolism
by: Tingting Li, et al.
Published: (2022-10-01) -
Academia / Industry Collaborations towards the Functionalization of Aryl Azoles
by: Simon Wagschal, et al.
Published: (2024-03-01) -
The new era of anticoagulation: factor XI and XII inhibitors
by: Domenico Prisco, et al.
Published: (2023-06-01) -
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
by: Anna C. Mavromanoli, et al.
Published: (2021-05-01)